Two high-growth small-caps I’d buy today

These two small-caps could produce significant gains for investors.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Advanced Medical Solutions (LSE: AMS) has proven itself to be one of the AIM’s top growth stocks over the past five years. 

Since 2012, the company’s revenue has grown from £52.6m to £82.6m and pre-tax profit has risen from £10.8m to £19.1m. Meanwhile, earnings per share have jumped from 5.4p to 7.8p. City analysts are expecting further growth in the years ahead. The company is projected to report revenue growth around 10% to £92.4m for 2017 and then further growth to £103m for 2018. A pre-tax profit of £25.5m is expected for 2018, up 150% from 2012’s figure of £10.8m. 

In a trading update issued today, management confirmed the company is on track to hit these targets as Advanced Medical grows through both acquisitions and organically.

Worth paying the price? 

Unfortunately, thanks to the company’s defensive nature and impressive growth, its shares are quite expensive. 

Based on current city forecasts shares in the company trade at a forward P/E of 33.9 and earnings per share growth of only 10% does little to justify this lofty valuation. The dividend payout of 1p per share for a yield of 0.3% is hardly a reason to buy either. 

Still, the one redeeming feature is the company’s hefty cash balance. At the end of 2016, Advanced Medical reported a net cash balance of £51.1m, up 49% year-on-year and equal to just under 10% of the company’s current £600m market capitalisation. Over the past five years, shares in the company have returned 330% excluding dividends.

Overall, if you’re looking for a highly defensive growth stock with more cash than it knows what to do with, and a record of producing returns for shareholders, Advanced Medical seems to be a great investment. Even though the shares might seem expensive, as Warren Buffett once said, “it’s far better to buy a wonderful company at a fair price than a fair company at a wonderful price.

Explosive growth rate

Quartix Holdings (LSE: QTX) looks to be an early stage Advanced Medical. Over the past five years, the company’s revenue has started to pick up, rising from £15.3m to £23.3m for 2016. Pre-tax profit has increased by £1.5m to £6.5m and earnings per share have grown from 8.5p to 12.9p. Pre-tax profit is expected to hit £6.7m this year before rising to £7.7m for 2018, and earnings per share are projected to increase to 13.5p over the same period. 

According to a trading update issued by the company this week, management believes that Quartix is on track to hit City forecasts for growth this year with new installations of its vehicle tracking systems growing by 40% during the six months to 30 June. With over 14,300 vehicles already using the group’s tracking systems, there is clearly a huge market out there for the tech. 

As management continues to pursue growth opportunities, investors should reap the rewards from further growth. Shares in Quatrix currently trade at a forward P/E of 32.6.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended Advanced Medical Solutions and Quartix. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Surely, the Rolls-Royce share price can’t go any higher in 2025?

The Rolls-Royce share price was the best performer on the FTSE 100 in 2023 and so far in 2024. Dr…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how an investor could start buying shares with £100 in January

Our writer explains some of the things he thinks investors on a limited budget should consider before they start buying…

Read more »

Investing Articles

Forget FTSE 100 airlines! I think shares in this company offer better value to consider

Stephen Wright thinks value investors looking for shares to buy should include aircraft leasing company Aercap. But is now the…

Read more »

Investing Articles

Are Rolls-Royce shares undervalued heading into 2025?

As the new year approaches, Rolls-Royce shares are the top holding of a US fund recommended by Warren Buffett. But…

Read more »

Investing Articles

£20k in a high-interest savings account? It could be earning more passive income in stocks

Millions of us want a passive income, but a high-interest savings account might not be the best way to do…

Read more »

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »